Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Taisho Pharmaceutical Co. said it operated in a difficult business environment in 2010, attributing weak sales to National Health Insurance price cuts and decreased demand for cold remedies
You may also be interested in...
Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company
Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company
Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues
TOKYO - Japanese pharma Eisai, Daiichi Sankyo and Mitsubishi Tanabe have had a rough seven days despite last week's slate of new drug approvals in Japan. Those approvals were capped with Mitsubishi Tanabe recalls and Eisai's discontinuation of a key Phase III trial